| 2010 Milion € | 2009 Milion € | Change % | |
| Sales | 4,422.8 | 4,028.2 | 9.8 |
| Profit After Functional Expenses | 485.2 | 444.5 | 9.1 |
| EBITDA | 700.5 | 620.5 | 12.9 |
| Research and Development Expenses | 155.4 | 139.1 | 11.7 |
| Equity | 1,984.0 | 1,620.0 | 22.5 |
| Equity Ratio (in %) | 42.3 | 40.8 | |
| Number of Employees (as of December 31, 2010) |
41,666* | 39,504 | 5.5 |
| Investment program | 1,600.0** |
* Number of Employees as of December 31, 2010
** starting in 2011
Financial year 2010 - the facts in brief
Sales: 4.422,8 million (+ 9,8 percent)
Profit After Functional Expenses: 485,2 million (+ 9,1 percent)
Operating Profit: 456,2 million (+ 11,1 percent)
Consolidated Annual Net Profit: 277,4 million (+ 15,8 percent)
Net Opertating Margin: 6,3 percent
Investments in Property, Plant and Equipment and Intangible Assets: 575,4 million (+ 26,5 percent)
Depreciation of Property, Plant and Equipment and Intangible Assets: 238,2 million (+ 14,2 percent)
Equity Ratio: 42,3 percent
Equity Ratio including Loans from Shareholders: 43,3 percent
Personnel Expenditure: 1.581,7 million (+ 11,0 percent)
Number of Employees (as of Dec 31, 2010): 41,666 (+ 5,5 percent)
The Hospital Care Division offers integrated therapy concepts of products and services for anaesthesia, intensive and acute care, infusion therapy and urology; annual sales of €2.086,7 million (+9,6 %).
Sales of the Aesculap Division, system supplier in the surgical area, rose to €1.281,1 million (+11,1 %)
Out Patient Market Division (OPM) offers concepts of comprehensive patient care for the segment of physicians in private practice as well as out-patient and stationary care. Annual sales of €554,6 million (+5,5 %).
B. Braun Avitum, active in the field of extracorporeal blood treatment and dialysis, provider of dialysis centers throughout Europe; sales of €474,8 million means an increase of 12,9 percent in comparison to the previous year.
